ANDOVER, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc., a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, (“TransMedics”) today announced the pricing of its upsized initial public offering of 5,690,000 shares of its common stock at a price to the public of $16.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on May 2, 2019, under the symbol “TMDX”. All of the shares are being offered by TransMedics.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by TransMedics, are expected to be $91,040,000. The offering is expected to close on May 6, 2019, subject to the satisfaction of customary closing conditions. In addition, TransMedics has granted the underwriters a 30-day option to purchase up to an additional 853,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Morgan Stanley and J.P. Morgan are acting as joint lead book-running managers for the offering. Cowen and Canaccord Genuity are acting as co-managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on May 1, 2019. This offering is being made only by means of a prospectus. A copy of the final prospectus, when available, may be obtained by visiting EDGAR on the SEC website at www.sec.gov or from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or J.P. Morgan Securities LLC, c/o J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone, at (866) 803-9204.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About TransMedics Group, Inc.

TransMedics is the world’s leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation, and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements include, without limitation, references to TransMedics’ expectations regarding the commencement of trading on the Nasdaq Global Market and the completion, timing and size of the public offering. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to completion of the public offering and the satisfaction of customary closing conditions related to the public offering. These and other risks and uncertainties are described more fully in the section captioned “Risk Factors” in the final prospectus related to the public offering to be filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and TransMedics undertakes no duty to update such information except as required under applicable law.

Investor Contact:
Greg Chodaczek or Lynn Lewis
646-924-1769
Investors@transmedics.com